Combogesic is a drug owned by Aft Pharmaceuticals Us Inc. It is protected by 3 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2039. Details of Combogesic's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11534407 | Pharmaceutical compostion containing acetominophen and ibuprofen |
Feb, 2039
(14 years from now) | Active |
| US11197830 | Pharmaceutical composition containing acetaminophen and ibuprofen |
Feb, 2039
(14 years from now) | Active |
| US10532036 | Combination composition |
Sep, 2025
(9 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Combogesic's patents.
Latest Legal Activities on Combogesic's Patents
Given below is the list of recent legal activities going on the following patents of Combogesic.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Jun, 2023 | US10532036 |
| Post Issue Communication - Certificate of Correction | 06 Jun, 2023 | US11534407 |
| Recordation of Patent Grant Mailed Critical | 27 Dec, 2022 | US11534407 |
| Patent Issue Date Used in PTA Calculation Critical | 27 Dec, 2022 | US11534407 |
| Email Notification Critical | 08 Dec, 2022 | US11534407 |
| Issue Notification Mailed Critical | 07 Dec, 2022 | US11534407 |
| Dispatch to FDC | 23 Nov, 2022 | US11534407 |
| Application Is Considered Ready for Issue Critical | 23 Nov, 2022 | US11534407 |
| Response to Reasons for Allowance | 18 Nov, 2022 | US11534407 |
| Issue Fee Payment Verified Critical | 18 Nov, 2022 | US11534407 |
FDA has granted several exclusivities to Combogesic. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Combogesic, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Combogesic.
Exclusivity Information
Combogesic holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Combogesic's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 01, 2026 |
US patents provide insights into the exclusivity only within the United States, but Combogesic is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combogesic's family patents as well as insights into ongoing legal events on those patents.
Combogesic's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combogesic's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 27, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combogesic Generic API suppliers:
Acetaminophen; Ibuprofen is the generic name for the brand Combogesic. 7 different companies have already filed for the generic of Combogesic, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combogesic's generic
Alternative Brands for Combogesic
Combogesic which is used for treating mild to moderate acute pain in adults through a combination of acetaminophen and ibuprofen., has several other brand drugs using the same active ingredient (Acetaminophen; Ibuprofen). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Haleon Us Holdings |
| |
| Hikma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Acetaminophen; Ibuprofen, Combogesic's active ingredient. Check the complete list of approved generic manufacturers for Combogesic
About Combogesic
Combogesic is a drug owned by Aft Pharmaceuticals Us Inc. It is used for treating mild to moderate acute pain in adults through a combination of acetaminophen and ibuprofen. Combogesic uses Acetaminophen; Ibuprofen as an active ingredient. Combogesic was launched by Aft Pharms Us in 2023.
Approval Date:
Combogesic was approved by FDA for market use on 01 March, 2023.
Active Ingredient:
Combogesic uses Acetaminophen; Ibuprofen as the active ingredient. Check out other Drugs and Companies using Acetaminophen; Ibuprofen ingredient
Treatment:
Combogesic is used for treating mild to moderate acute pain in adults through a combination of acetaminophen and ibuprofen.
Dosage:
Combogesic is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 325MG;97.5MG | TABLET | Prescription | ORAL |